Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas

Oncogene volume 22, pages 6111–6114 (2003)Cite this article

Abstract

Thyroid adenomas belong to the cytogenetically best investigated human epithelial tumors. Cytogenetic studies of about 450 benign lesions allow one to distinguish between different cytogenetic subgroups. Two chromosomal regions, that is, 19q13 and 2p21, are frequently rearranged in these tumors. Although 2p21 aberrations only account for about 10% of the benign thyroid tumors with clonal cytogenetic deviations, 2p21 rearrangements belong to the most common cytogenetic rearrangements in epithelial tumors due to the high frequency of these benign lesions. The 2p21 breakpoint region recently has been delineated to a region of 450 kbp, but the gene affected by the cytogenetic rearrangements still has escaped detection. Positional cloning and 3′ RACE–PCR allowed us to clone that gene which we will refer to as thyroid adenoma associated (THADA) gene. In cells from two thyroid adenomas characterized by translocations t(2;20;3) (p21;q11.2;p25) and t(2;7)(p21;p15), respectively, we performed 3′-RACE–PCRs and found two fusions of THADA with a sequence derived from chromosome band 3p25 or with a sequence derived from chromosome band 7p15. The THADA gene spans roughly 365 kbp and, based on preliminary results, encodes a death receptor-interacting protein.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W and Lipman DJ . (1997). Nucleic Acids Res., 25, 3389–3402.

  • Bartnitzke S, Herrmann ME, Lobeck H, Zuschneid W, Neuhaus P and Bullerdiek J . (1989). Cancer Genet. Cytogenet., 39, 65–68.

  • Belge G, Kazmierczak B, Meyer-Bolte K, Bartnitzke S and Bullerdiek J . (1992). Cell. Biol. Int. Rep., 16, 339–347.

  • Belge G, Rippe V, Meiboom M, Drieschner N, Garcia E and Bullerdiek J . (2001). Cytogenet. Cell Genet., 93, 48–51.

  • Belge G, Roque L, Soares J, Bruckmann S, Thode B, Fonseca E, Clode A, Bartnitzke S, Castedo S and Bullerdiek J . (1998). Cancer Genet. Cytogenet., 101, 42–48.

  • Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O and Myklebost O . (1997). Oncogene, 14, 2935–2941.

  • Bol S, Belge G, Rippe V and Bullerdiek J . (2001). Cytogenet. Cell Genet., 95, 189–191.

  • Bol S, Belge G, Thode B, Bartnitzke S and Bullerdiek J . (1999). Cancer Genet. Cytogenet., 114, 75–77.

  • Bondeson L, Bengtsson A, Bondeson AG, Dahlenfors R, Grimelius L, Wedell B and Mark J . (1989). Cancer, 64, 680–685.

  • Bullerdiek J, Böschen C and Bartnitzke S . (1987). Cancer Genet. Cytogenet., 24, 205–212.

  • Dal Cin P, Sneyers W, Aly MS, Segers A, Ostijn F, Van Damme B and Van den Berghe H . (1992). Cancer Genet. Cytogenet., 60, 99–101.

  • Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M and Fusco A . (1998). Oncogene, 17, 413–418.

  • Feinberg AP and Vogelstein B . (1983). Anal. Biochem., 132, 6–13.

  • Kievits T, Dauwerse JG, Wiegant J, Devilee P, Breuning MH, Cornelisse CJ, Van Ommen GJ and Pearson PL . (1990). Cytogenet. Cell Genet., 53, 134–136.

  • Rippe V, Belge G, Meiboom M, Kazmierczak B, Fusco A and Bullerdiek J . (1999). Genes Chromosomes Cancer, 26, 229–236.

  • Teyssier JR, Liautaud-Roger F, Ferre D, Patey M and Dufer J . (1990). Cancer Genet. Cytogenet., 50, 249–263.

Download references

Acknowledgements

We thank Jessica Hommes for technical assistance.

Author information

Authors and Affiliations

  1. Center for Human Genetics, University of Bremen, Leobener Str. ZHG, Bremen, D-28359, Germany

    Volkhard Rippe, Norbert Drieschner, Maren Meiboom, Hugo Murua Escobar, Gazanfer Belge & Jörn Bullerdiek

  2. Institute of Pathology, Central Hospital Bremen-Nord, Bremen, Germany

    Ulrich Bonk

Authors
  1. Volkhard Rippe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norbert Drieschner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maren Meiboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hugo Murua Escobar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ulrich Bonk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gazanfer Belge
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jörn Bullerdiek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörn Bullerdiek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rippe, V., Drieschner, N., Meiboom, M. et al. Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene 22, 6111–6114 (2003). https://doi.org/10.1038/sj.onc.1206867

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206867

Keywords

This article is cited by

Search

Advanced search

Quick links